All Oncology News

Venetoclax plus obinutuzumab led to higher undetectable minimal residual disease rates in previously untreated chronic lymphocytic leukemia.

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.

Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.

Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

Patients with systemic mastocytosis experienced superior OS and DOT outcomes with first- and later-line avapritinib vs midostaurin and BAT, respectively.

The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

The Canning Thoracic Institute became the highest-volume lung transplant center in the US and achieved the shortest wait time for a lung transplant.

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Yale Medicine was ranked third in the nation for physician practices, an annual designation by Castle Connolly.

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

A chatbot-based approach was equivalent to SOC pretest cancer genetic services and genetic testing among individuals eligible for cancer genetic testing.

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.